OpenAI Snaps Up TBPN, Slashes ChatGPT Pricing As Secondary Market Interest Fades
Update (1400ET): In a surprise move, OpenAI has acquired TBPN (Technology Business Programming Network), the influential daily technology talk show and media platform hosted by John Coogan and Jordi Hays. TBPN has become one of Silicon Valley’s most-watched programs for real-time tech news, M&A rumors, high-profile executive interviews, and AI developments – often described as “SportsCenter for the tech industry.” The deal gives OpenAI a powerful owned-media channel to directly reach and engage the tech community while accelerating global conversations around AI. The show will continue unchanged: live weekdays from 11 a.m. to 2 p.m. PT on YouTube and X, with Coogan and Hays retaining full creative control and editorial independence.
TBPN has been acquired by OpenAI
The world is changing quickly but TBPN will stay the same. Live every weekday just with a lot more resources.
Thank you to everyone that has been a part of this journey big or small. We are 17 months in and unironically just getting started. pic.twitter.com/TLvPxxMGVe
— Jordi Hays (@jordihays) April 2, 2026
Coogan, who has a long personal history with OpenAI CEO Sam Altman (including funding from Altman for his earlier startups), called the acquisition a “full circle moment.” Both hosts emphasized that TBPN “will stay the same” but will now benefit from significantly more resources to scale.
TBPN has been acquired by OpenAI!
The show is staying the same and we’ll continue to go live at 11am pacific every weekday.
This is a full circle moment for me as I’ve worked with @sama for well over a decade. He funded my first company in 2013. Then helped us fix a serious…
— John Coogan (@johncoogan) April 2, 2026
At the same time, OpenAI is accelerating its consumer growth push by expanding access to its lower-priced ChatGPT Go subscription tier. Priced at roughly $8 per month in the US (a ~60% discount to the $20 ChatGPT Plus plan), Go delivers expanded access to GPT-5.3, higher message limits, more file uploads, image generation, and longer memory. The tier – first introduced in select markets last year and rolled out globally earlier in 2026 — is now being made available in dozens of additional countries as OpenAI seeks to drive mass adoption and daily usage ahead of intensifying competition.
These announcements appear designed to bolster OpenAI’s growth narrative and consumer momentum at a moment when secondary-market demand for its shares has cooled sharply (as detailed in our reporting below).
* * *
Interest in OpenAI’s stock on secondary markets has cooled sharply, with some large investors now struggling to find buyers according to Bloomberg.
At the same time, capital is rapidly shifting toward its main rival, Anthropic, where demand is surging.
In recent weeks, holders of OpenAI shares—including hedge funds and venture firms—have tried to offload roughly $600 million in stock, but unlike before, buyers haven’t stepped in. Platforms that once saw quick turnover now report little to no interest. Meanwhile, investors are actively setting aside billions to gain exposure to Anthropic instead.
Much of this shift comes down to valuation and perceived upside. OpenAI’s valuation has climbed to around $852 billion, leaving some investors unsure how much room remains for near-term gains. Anthropic, valued significantly lower, is increasingly viewed as having more growth potential, making it a more attractive bet right now.
The Bloomberg report notes that major banks like Morgan Stanley and Goldman Sachs are adjusting—offering OpenAI shares with reduced fees to spark interest, while continuing to charge typical performance fees for Anthropic investments.
There are also strategic concerns. OpenAI is spending heavily on infrastructure and has been slower to expand into high-margin enterprise markets. Anthropic, by contrast, has gained stronger traction with those clients, reinforcing expectations of faster growth.
That said, Anthropic isn’t without issues, including legal disputes and recent security missteps. Still, investor appetite remains extremely strong, with secondary demand pushing its implied valuation far higher, while OpenAI shares are increasingly trading at a discount.
*OPENAI DEMAND SINKS ON SECONDARY MARKET AS ANTHROPIC RUNS HOT
OpenAI shares are being sold in the secondary markets per Bloomberg with no buyers, while Anthropic shares are seeing record demand.
Ken Smythe, the founder of Next Round Capital, noted that there was a huge drop in… pic.twitter.com/MqygdTbzkn
— Negligible Capital (@negligible_cap) April 1, 2026
Tyler Durden Thu, 04/02/2026 – 14:20
Source: https://freedombunker.com/2026/04/02/openai-snaps-up-tbpn-slashes-chatgpt-pricing-as-secondary-market-interest-fades/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.



